LifeVantage Key Executives
This section highlights LifeVantage's key executives, including their titles and compensation details.
Find Contacts at LifeVantage
(Showing 0 of )
LifeVantage Earnings
This section highlights LifeVantage's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2025 | 2025-02-05 | $0.13 | $0.22 |
| Read Transcript | Q1 | 2025 | 2024-10-29 | $0.15 | $0.15 |
| Read Transcript | Q4 | 2024 | 2024-08-28 | $0.21 | $0.14 |
| Read Transcript | Q3 | 2024 | 2024-05-03 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-01-30 | $0.04 | $0.10 |
| Read Transcript | Q1 | 2024 | 2023-11-09 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2023-08-28 | $0.20 | $0.17 |
| Read Transcript | Q3 | 2023 | 2023-05-07 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-02-02 | $0.05 | $-0.07 |
| Read Transcript | Q1 | 2023 | 2022-11-06 | N/A | N/A |
LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.
$14.61
Stock Price
$183.37M
Market Cap
222
Employees
Lehi, UT
Location
Financial Statements
Access annual & quarterly financial statements for LifeVantage, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $200.16M | $213.40M | $206.36M | $220.18M | $232.91M |
| Cost of Revenue | $41.44M | $43.39M | $38.10M | $38.19M | $37.96M |
| Gross Profit | $158.72M | $170.01M | $168.26M | $181.99M | $194.95M |
| Gross Profit Ratio | 79.30% | 79.70% | 81.54% | 82.70% | 83.70% |
| Research and Development Expenses | $- | $600.00K | $700.00K | $700.00K | $900.00K |
| General and Administrative Expenses | $68.47M | $71.06M | $63.42M | $60.84M | $67.91M |
| Selling and Marketing Expenses | $85.92M | $94.69M | $97.26M | $103.54M | $111.57M |
| Selling General and Administrative Expenses | $154.39M | $165.75M | $160.69M | $164.38M | $179.49M |
| Other Expenses | $- | $-458.00K | $-669.00K | $-366.00K | $-685.00K |
| Operating Expenses | $154.39M | $165.75M | $160.69M | $164.38M | $179.49M |
| Cost and Expenses | $195.83M | $209.14M | $198.78M | $202.57M | $217.45M |
| Interest Income | $430.00K | $198.00K | $10.00K | $17.00K | $120.00K |
| Interest Expense | $- | $198.00K | $10.00K | $17.00K | $120.00K |
| Depreciation and Amortization | $3.58M | $5.33M | $5.05M | $5.83M | $5.10M |
| EBITDA | $7.93M | $4.26M | $9.75M | $23.07M | $19.88M |
| EBITDA Ratio | 3.96% | 2.00% | 3.35% | 7.83% | 6.35% |
| Operating Income | $4.33M | $4.26M | $1.86M | $11.42M | $9.68M |
| Operating Income Ratio | 2.16% | 2.00% | 0.90% | 5.19% | 4.16% |
| Total Other Income Expenses Net | $18.00K | $-260.00K | $-2.88M | $-383.00K | $-805.00K |
| Income Before Tax | $4.35M | $4.00M | $4.69M | $17.23M | $14.66M |
| Income Before Tax Ratio | 2.17% | 1.87% | 2.27% | 7.83% | 6.29% |
| Income Tax Expense | $1.41M | $1.46M | $1.57M | $4.34M | $3.11M |
| Net Income | $2.94M | $2.54M | $3.12M | $12.89M | $11.55M |
| Net Income Ratio | 1.47% | 1.19% | 1.51% | 5.86% | 4.96% |
| EPS | $0.24 | $0.20 | $0.24 | $0.92 | $0.82 |
| EPS Diluted | $0.23 | $0.20 | $0.24 | $0.90 | $0.79 |
| Weighted Average Shares Outstanding | 12.46M | 12.56M | 12.89M | 14.07M | 14.11M |
| Weighted Average Shares Outstanding Diluted | 12.99M | 12.57M | 13.07M | 14.27M | 14.60M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.76M | $47.21M | $48.93M | $48.24M | $51.62M | $51.36M | $54.22M | $53.74M | $53.66M | $51.77M | $50.94M | $50.00M | $52.19M | $53.22M | $54.78M | $51.57M | $59.01M | $54.83M | $59.37M | $56.08M |
| Cost of Revenue | $13.20M | $9.49M | $10.02M | $10.17M | $11.07M | $10.18M | $11.07M | $10.62M | $11.76M | $9.94M | $9.33M | $9.66M | $9.68M | $9.43M | $9.78M | $8.82M | $10.19M | $9.40M | $9.45M | $9.10M |
| Gross Profit | $54.57M | $37.72M | $38.91M | $38.07M | $40.56M | $41.18M | $43.15M | $43.12M | $41.90M | $41.83M | $41.61M | $40.35M | $42.51M | $43.79M | $44.99M | $42.75M | $48.82M | $45.43M | $49.92M | $46.98M |
| Gross Profit Ratio | 80.53% | 79.90% | 79.50% | 78.90% | 78.60% | 80.20% | 79.60% | 80.20% | 78.10% | 80.80% | 81.70% | 80.70% | 81.50% | 82.30% | 82.10% | 82.90% | 82.70% | 82.90% | 84.08% | 83.78% |
| Research and Development Expenses | $- | $- | $500.00K | $200.00K | $100.00K | $200.00K | $200.00K | $200.00K | $200.00K | $100.00K | $100.00K | $100.00K | $200.00K | $200.00K | $100.00K | $200.00K | $200.00K | $200.00K | $100.00K | $200.00K |
| General and Administrative Expenses | $18.61M | $14.85M | $14.02M | $16.43M | $20.07M | $17.96M | $17.05M | $17.71M | $19.58M | $16.73M | $15.61M | $15.32M | $17.42M | $15.08M | $12.81M | $15.51M | $16.22M | $16.30M | $14.82M | $17.28M |
| Selling and Marketing Expenses | $- | $20.30M | $21.98M | $19.71M | $21.75M | $22.47M | $23.50M | $23.82M | $23.56M | $23.81M | $24.50M | $23.21M | $25.45M | $24.11M | $25.60M | $25.15M | $27.15M | $25.63M | $28.89M | $26.67M |
| Selling General and Administrative Expenses | $18.61M | $35.15M | $36.00M | $35.94M | $41.82M | $40.44M | $40.55M | $41.52M | $43.14M | $40.54M | $40.12M | $38.52M | $42.87M | $39.18M | $38.41M | $40.66M | $43.37M | $41.93M | $43.71M | $43.95M |
| Other Expenses | $32.52M | $- | $152.00K | $-89.00K | $41.00K | $-88.00K | $-154.00K | $7.00K | $125.00K | $-438.00K | $-284.00K | $-69.00K | $-139.00K | $-177.00K | $-103.00K | $-255.00K | $133.00K | $-141.00K | $-120.00K | $-337.00K |
| Operating Expenses | $51.14M | $35.15M | $36.00M | $36.14M | $41.82M | $40.44M | $40.55M | $41.52M | $43.14M | $40.54M | $40.12M | $38.52M | $42.87M | $39.18M | $38.41M | $40.66M | $43.37M | $41.93M | $43.71M | $43.95M |
| Cost and Expenses | $64.33M | $44.64M | $46.02M | $46.31M | $52.88M | $50.62M | $51.62M | $52.14M | $54.89M | $50.48M | $49.45M | $48.18M | $52.55M | $48.61M | $48.20M | $49.48M | $53.56M | $51.33M | $53.16M | $53.04M |
| Interest Income | $130.00K | $59.00K | $78.00K | $76.00K | $108.00K | $168.00K | $107.00K | $59.00K | $32.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $107.00K | $59.00K | $32.00K | $- | $- | $5.00K | $1.00K | $3.00K | $17.00K | $2.00K | $9.00K | $6.00K | $1.00K | $30.00K |
| Depreciation and Amortization | $- | $797.00K | $806.00K | $895.00K | $962.00K | $918.00K | $1.39M | $1.36M | $1.59M | $984.00K | $1.38M | $987.00K | $1.33M | $1.35M | $966.00K | $1.40M | $1.21M | $2.25M | $1.42M | $1.29M |
| EBITDA | $3.43M | $3.38M | $3.72M | $2.83M | $-299.00K | $1.67M | $3.95M | $1.60M | $-264.00K | $1.29M | $382.00K | $2.74M | $975.00K | $5.79M | $7.44M | $3.23M | $6.79M | $5.60M | $7.50M | $3.99M |
| EBITDA Ratio | 5.06% | 7.15% | 7.59% | 5.86% | -0.58% | 3.25% | 4.80% | 2.98% | 0.66% | 3.55% | 2.38% | 5.49% | 1.60% | 10.87% | 11.83% | 6.27% | 11.52% | 10.22% | 10.26% | 4.81% |
| Operating Income | $3.43M | $2.57M | $2.91M | $1.93M | $-1.26M | $749.00K | $2.60M | $234.00K | $-1.23M | $852.00K | $1.50M | $1.82M | $-358.00K | $4.61M | $6.58M | $2.09M | $5.45M | $3.50M | $6.21M | $3.03M |
| Operating Income Ratio | 5.06% | 5.44% | 5.95% | 4.01% | -2.44% | 1.46% | 4.80% | 0.44% | -2.30% | 1.65% | 2.94% | 3.65% | -0.69% | 8.67% | 12.01% | 4.05% | 9.23% | 6.38% | 10.46% | 5.41% |
| Total Other Income Expenses Net | $-339.00K | $8.00K | $-199.00K | $-13.00K | $149.00K | $80.00K | $-47.00K | $66.00K | $157.00K | $-438.00K | $-2.49M | $-74.00K | $-140.00K | $-180.00K | $-103.00K | $-257.00K | $124.00K | $-147.00K | $-121.00K | $-367.00K |
| Income Before Tax | $3.09M | $2.58M | $2.71M | $1.92M | $-1.11M | $829.00K | $2.56M | $1.67M | $-1.07M | $852.00K | $-993.00K | $1.75M | $-498.00K | $4.43M | $6.48M | $1.83M | $5.57M | $3.35M | $6.09M | $2.67M |
| Income Before Tax Ratio | 4.56% | 5.46% | 5.54% | 3.98% | -2.15% | 1.61% | 4.71% | 3.10% | -2.00% | 1.65% | -1.95% | 3.50% | -0.95% | 8.33% | 11.83% | 3.55% | 9.44% | 6.11% | 10.25% | 4.75% |
| Income Tax Expense | $539.00K | $752.00K | $1.41M | $262.00K | $-456.00K | $200.00K | $590.00K | $643.00K | $-17.00K | $242.00K | $423.00K | $610.00K | $-577.00K | $1.12M | $1.57M | $107.00K | $1.76M | $899.00K | $2.26M | $1.00M |
| Net Income | $2.55M | $1.83M | $1.30M | $1.66M | $-656.00K | $629.00K | $1.97M | $1.02M | $-1.06M | $610.00K | $-1.42M | $1.14M | $79.00K | $3.32M | $4.91M | $1.72M | $3.81M | $2.45M | $3.82M | $1.66M |
| Net Income Ratio | 3.76% | 3.87% | 2.67% | 3.44% | -1.27% | 1.22% | 3.63% | 1.90% | -1.97% | 1.18% | -2.78% | 2.28% | 0.15% | 6.23% | 8.96% | 3.34% | 6.46% | 4.47% | 6.44% | 2.96% |
| EPS | $0.21 | $0.15 | $0.11 | $0.13 | $-0.05 | $0.05 | $0.16 | $0.08 | $-0.08 | $0.05 | $-0.12 | $0.09 | $0.01 | $0.25 | $0.36 | $0.12 | $0.27 | $0.17 | $0.27 | $0.12 |
| EPS Diluted | $0.19 | $0.14 | $0.32 | $0.13 | $-0.05 | $0.05 | $0.16 | $0.08 | $-0.08 | $0.05 | $-0.11 | $0.09 | $0.01 | $0.25 | $0.35 | $0.12 | $0.26 | $0.17 | $0.26 | $0.11 |
| Weighted Average Shares Outstanding | 12.21M | 12.16M | 12.26M | 12.42M | 12.61M | 12.54M | 12.62M | 12.62M | 12.54M | 12.46M | 11.76M | 13.20M | 13.20M | 13.39M | 13.75M | 14.07M | 14.19M | 14.27M | 14.26M | 14.25M |
| Weighted Average Shares Outstanding Diluted | 13.18M | 12.82M | 12.87M | 12.99M | 12.61M | 13.11M | 12.62M | 12.77M | 12.54M | 12.49M | 12.34M | 13.26M | 13.29M | 13.47M | 13.88M | 14.21M | 14.44M | 14.70M | 14.70M | 14.69M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $16.89M | $21.61M | $20.19M | $23.17M | $22.14M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $16.89M | $21.61M | $20.19M | $23.17M | $22.14M |
| Net Receivables | $3.26M | $1.85M | $5.09M | $3.96M | $2.61M |
| Inventory | $15.05M | $16.07M | $16.47M | $16.14M | $13.89M |
| Other Current Assets | $2.44M | $4.75M | $5.21M | $4.77M | $10.46M |
| Total Current Assets | $37.65M | $44.28M | $46.96M | $48.05M | $43.87M |
| Property Plant Equipment Net | $17.38M | $17.82M | $20.54M | $24.82M | $8.13M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $323.00K | $455.00K | $587.00K | $719.00K | $851.00K |
| Goodwill and Intangible Assets | $323.00K | $455.00K | $587.00K | $719.00K | $851.00K |
| Long Term Investments | $- | $- | $- | $2.21M | $2.21M |
| Tax Assets | $4.27M | $2.99M | $1.29M | $1.21M | $2.16M |
| Other Non-Current Assets | $680.00K | $569.00K | $1.33M | $1.72M | $1.66M |
| Total Non-Current Assets | $22.65M | $21.84M | $23.75M | $30.68M | $15.01M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $60.30M | $66.12M | $70.71M | $78.73M | $58.88M |
| Account Payables | $5.85M | $3.50M | $7.46M | $6.74M | $3.52M |
| Short Term Debt | $3.62M | $3.04M | $5.20M | $4.30M | $2.37M |
| Tax Payables | $2.46M | $1.73M | $453.00K | $830.00K | $784.00K |
| Deferred Revenue | $860.00K | $834.00K | $78.00K | $319.00K | $792.00K |
| Other Current Liabilities | $9.51M | $10.50M | $12.53M | $13.00M | $17.55M |
| Total Current Liabilities | $22.31M | $19.61M | $25.73M | $25.20M | $25.02M |
| Long Term Debt | $11.80M | $23.13M | $26.31M | $32.06M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $198.00K | $-11.27M | $-12.85M | $-15.34M | $604.00K |
| Total Non-Current Liabilities | $12.00M | $11.87M | $13.46M | $16.73M | $604.00K |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $34.31M | $31.47M | $39.19M | $41.92M | $25.62M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-108.74M | $-98.31M | $-98.44M | $-92.35M | $-93.31M |
| Accumulated Other Comprehensive Income Loss | $-1.92M | $-1.36M | $-1.12M | $104.00K | $144.00K |
| Other Total Stockholders Equity | $136.64M | $134.31M | $131.07M | $129.05M | $126.42M |
| Total Stockholders Equity | $25.99M | $34.65M | $31.52M | $36.81M | $33.25M |
| Total Equity | $25.99M | $34.65M | $31.52M | $36.81M | $33.25M |
| Total Liabilities and Stockholders Equity | $60.30M | $66.12M | $70.71M | $78.73M | $58.88M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $60.30M | $66.12M | $70.71M | $78.73M | $58.88M |
| Total Investments | $- | $- | $- | $2.21M | $2.21M |
| Total Debt | $13.61M | $13.09M | $15.76M | $18.18M | $1.18M |
| Net Debt | $-3.27M | $-8.52M | $-4.43M | $-4.99M | $-20.95M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $21.59M | $14.60M | $16.89M | $17.38M | $17.33M | $18.41M | $21.61M | $19.53M | $17.37M | $17.62M | $20.19M | $17.80M | $20.17M | $19.93M | $23.17M | $18.95M | $19.73M | $17.96M | $22.14M | $13.46M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $21.59M | $14.60M | $16.89M | $17.38M | $17.33M | $18.41M | $21.61M | $19.53M | $17.37M | $17.62M | $20.19M | $17.80M | $20.17M | $19.93M | $23.17M | $18.95M | $19.73M | $17.96M | $22.14M | $13.46M |
| Net Receivables | $2.09M | $2.97M | $3.26M | $2.50M | $2.57M | $2.65M | $1.85M | $3.02M | $3.30M | $1.92M | $5.09M | $3.60M | $3.31M | $3.25M | $3.96M | $4.07M | $3.81M | $2.44M | $2.61M | $3.55M |
| Inventory | $17.47M | $16.91M | $15.05M | $15.16M | $14.97M | $15.71M | $16.07M | $18.45M | $20.43M | $18.64M | $16.47M | $16.28M | $15.43M | $16.08M | $16.14M | $14.82M | $14.71M | $14.80M | $13.89M | $14.74M |
| Other Current Assets | $4.64M | $4.34M | $2.44M | $2.76M | $3.79M | $5.14M | $4.75M | $3.35M | $3.25M | $9.50M | $5.21M | $7.38M | $3.87M | $11.28M | $4.77M | $5.77M | $4.22M | $5.83M | $10.46M | $6.08M |
| Total Current Assets | $45.79M | $38.81M | $37.65M | $37.80M | $38.66M | $41.90M | $44.28M | $44.34M | $44.36M | $42.92M | $46.96M | $45.06M | $42.79M | $44.90M | $48.05M | $43.62M | $42.46M | $41.03M | $43.87M | $37.84M |
| Property Plant Equipment Net | $16.05M | $16.89M | $17.38M | $17.73M | $18.50M | $19.11M | $17.82M | $18.70M | $19.06M | $19.81M | $20.54M | $21.80M | $22.91M | $23.82M | $24.82M | $25.01M | $25.06M | $21.59M | $8.13M | $8.92M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $257.00K | $290.00K | $323.00K | $356.00K | $389.00K | $422.00K | $455.00K | $488.00K | $521.00K | $554.00K | $587.00K | $620.00K | $653.00K | $686.00K | $719.00K | $752.00K | $785.00K | $818.00K | $851.00K | $884.00K |
| Goodwill and Intangible Assets | $257.00K | $290.00K | $323.00K | $356.00K | $389.00K | $422.00K | $455.00K | $488.00K | $521.00K | $554.00K | $587.00K | $620.00K | $653.00K | $686.00K | $719.00K | $752.00K | $785.00K | $818.00K | $851.00K | $884.00K |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M |
| Tax Assets | $5.78M | $4.78M | $4.27M | $4.93M | $4.62M | $4.69M | $2.99M | $2.24M | $2.52M | $3.04M | $1.29M | $1.08M | $2.03M | $2.29M | $1.21M | $1.82M | $1.87M | $2.42M | $2.16M | $941.00K |
| Other Non-Current Assets | $645.00K | $685.00K | $680.00K | $496.00K | $518.00K | $476.00K | $569.00K | $1.31M | $1.38M | $1.27M | $1.33M | $1.46M | $1.66M | $1.70M | $1.72M | $1.71M | $2.05M | $2.15M | $1.66M | $1.55M |
| Total Non-Current Assets | $22.74M | $22.64M | $22.65M | $23.51M | $24.02M | $24.70M | $21.84M | $22.74M | $23.48M | $24.68M | $23.75M | $27.16M | $29.46M | $30.69M | $30.68M | $31.50M | $31.97M | $29.18M | $15.01M | $14.50M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $68.53M | $61.46M | $60.30M | $61.31M | $62.68M | $66.60M | $66.12M | $67.08M | $67.83M | $67.60M | $70.71M | $72.22M | $72.25M | $75.60M | $78.73M | $75.12M | $74.43M | $70.21M | $58.88M | $52.33M |
| Account Payables | $5.76M | $5.27M | $5.85M | $6.95M | $6.24M | $6.76M | $3.50M | $5.82M | $8.23M | $7.85M | $7.46M | $6.53M | $4.87M | $4.84M | $6.74M | $5.16M | $5.16M | $4.73M | $3.52M | $4.00M |
| Short Term Debt | $1.89M | $1.90M | $3.62M | $3.35M | $3.29M | $3.32M | $3.04M | $1.77M | $2.01M | $4.79M | $5.20M | $5.38M | $5.43M | $4.89M | $4.30M | $1.64M | $4.10M | $4.60M | $2.37M | $3.69M |
| Tax Payables | $660.00K | $47.00K | $202.00K | $772.00K | $825.00K | $1.52M | $1.73M | $- | $- | $107.00K | $453.00K | $78.00K | $369.00K | $1.47M | $830.00K | $358.00K | $651.00K | $603.00K | $784.00K | $- |
| Deferred Revenue | $- | $- | $860.00K | $700.00K | $825.00K | $1.52M | $834.00K | $- | $2.52M | $3.04M | $78.00K | $- | $- | $1.47M | $319.00K | $358.00K | $1.87M | $603.00K | $792.00K | $- |
| Other Current Liabilities | $19.25M | $14.86M | $11.77M | $11.40M | $12.66M | $13.09M | $10.50M | $13.80M | $13.10M | $10.02M | $12.53M | $11.62M | $11.50M | $11.07M | $13.00M | $15.12M | $12.55M | $12.09M | $17.55M | $15.63M |
| Total Current Liabilities | $27.55M | $22.07M | $22.31M | $22.48M | $23.02M | $24.70M | $19.61M | $21.40M | $23.33M | $22.77M | $25.73M | $23.61M | $22.17M | $22.27M | $25.20M | $22.28M | $22.45M | $22.02M | $25.02M | $23.32M |
| Long Term Debt | $10.88M | $11.47M | $11.80M | $23.70M | $24.27M | $24.92M | $23.13M | $11.92M | $12.28M | $25.28M | $26.31M | $27.75M | $29.22M | $30.64M | $32.06M | $32.39M | $15.41M | $13.16M | $- | $23.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $206.00K | $225.00K | $198.00K | $-11.64M | $-11.91M | $-12.31M | $-11.27M | $319.00K | $321.00K | $-12.34M | $-12.85M | $-13.18M | $-13.91M | $-14.63M | $-15.34M | $-15.18M | $1.05M | $896.00K | $604.00K | $388.00K |
| Total Non-Current Liabilities | $11.09M | $11.69M | $12.00M | $12.06M | $12.36M | $12.61M | $11.87M | $12.24M | $12.60M | $12.94M | $13.46M | $14.58M | $15.30M | $16.01M | $16.73M | $17.21M | $16.46M | $14.06M | $604.00K | $411.00K |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $38.64M | $33.76M | $34.31M | $34.54M | $35.38M | $37.31M | $31.47M | $33.64M | $35.94M | $35.71M | $39.19M | $38.18M | $37.47M | $38.29M | $41.92M | $39.49M | $38.91M | $36.08M | $25.62M | $23.73M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-106.48M | $-108.53M | $-108.74M | $-107.71M | $-106.99M | $-104.00M | $-98.31M | $-99.00M | $-99.64M | $-98.20M | $-98.44M | $-96.18M | $-95.60M | $-92.52M | $-92.35M | $-93.32M | $-93.04M | $-92.86M | $-93.31M | $-97.13M |
| Accumulated Other Comprehensive Income Loss | $-1.80M | $-1.12M | $-1.92M | $-1.72M | $-1.19M | $-1.66M | $-1.36M | $-979.00K | $-993.00K | $-1.63M | $-1.12M | $-500.00K | $-210.00K | $-31.00K | $104.00K | $105.00K | $548.00K | $304.00K | $144.00K | $32.00K |
| Other Total Stockholders Equity | $138.17M | $137.35M | $136.64M | $136.20M | $135.49M | $134.95M | $134.31M | $133.42M | $132.53M | $131.73M | $131.07M | $130.71M | $130.59M | $129.86M | $129.05M | $128.84M | $128.01M | $126.69M | $126.42M | $125.70M |
| Total Stockholders Equity | $29.89M | $27.70M | $25.99M | $26.77M | $27.31M | $29.29M | $34.65M | $33.44M | $31.89M | $31.89M | $31.52M | $34.03M | $34.78M | $37.31M | $36.81M | $35.63M | $35.52M | $34.14M | $33.25M | $28.60M |
| Total Equity | $29.89M | $27.70M | $25.99M | $26.77M | $27.31M | $29.29M | $34.65M | $33.44M | $31.89M | $31.89M | $31.52M | $34.03M | $34.78M | $37.31M | $36.81M | $35.63M | $35.52M | $34.14M | $33.25M | $28.60M |
| Total Liabilities and Stockholders Equity | $68.53M | $61.46M | $60.30M | $61.31M | $62.68M | $66.60M | $66.12M | $67.08M | $67.83M | $67.60M | $70.71M | $72.22M | $72.25M | $75.60M | $78.73M | $75.12M | $74.43M | $70.21M | $58.88M | $52.33M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $68.53M | $61.46M | $60.30M | $61.31M | $62.68M | $66.60M | $66.12M | $67.08M | $67.83M | $67.60M | $70.71M | $72.22M | $72.25M | $75.60M | $78.73M | $75.12M | $74.43M | $70.21M | $58.88M | $52.33M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M | $2.21M |
| Total Debt | $12.77M | $13.36M | $13.61M | $13.53M | $13.78M | $14.12M | $13.09M | $13.69M | $14.29M | $15.04M | $15.76M | $16.56M | $17.32M | $17.77M | $18.18M | $17.83M | $17.46M | $15.46M | $1.18M | $1.87M |
| Net Debt | $-8.83M | $-1.23M | $-3.27M | $-3.85M | $-3.55M | $-4.29M | $-8.52M | $-5.84M | $-3.08M | $-2.58M | $-4.43M | $-1.23M | $-2.85M | $-2.16M | $-4.99M | $-1.12M | $-2.27M | $-2.50M | $-20.95M | $-11.60M |
Annual Cash Flow
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $2.94M | $2.54M | $3.12M | $12.89M | $11.55M |
| Depreciation and Amortization | $3.58M | $3.58M | $5.05M | $5.83M | $5.10M |
| Deferred Income Tax | $-1.28M | $-1.70M | $-81.00K | $955.00K | $364.00K |
| Stock Based Compensation | $3.28M | $3.19M | $1.77M | $2.04M | $4.92M |
| Change in Working Capital | $2.38M | $-2.56M | $-4.10M | $-5.43M | $-3.65M |
| Accounts Receivables | $-1.42M | $1.56M | $-614.00K | $-265.00K | $-539.00K |
| Inventory | $662.00K | $61.00K | $-1.19M | $-2.07M | $-152.00K |
| Accounts Payables | $2.30M | $-3.98M | $824.00K | $3.21M | $-1.65M |
| Other Working Capital | $841.00K | $-195.00K | $-3.12M | $-6.31M | $-1.31M |
| Other Non Cash Items | $1.30M | $1.78M | $2.21M | $-7.00K | $46.00K |
| Net Cash Provided by Operating Activities | $12.20M | $6.83M | $7.96M | $16.27M | $18.33M |
| Investments in Property Plant and Equipment | $-2.25M | $-3.07M | $-1.53M | $-3.74M | $-2.68M |
| Acquisitions Net | $- | $8.00K | $- | $7.00K | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $8.00K | $-1.53M | $7.00K | $-2.68M |
| Net Cash Used for Investing Activities | $-2.25M | $-3.06M | $-1.53M | $-3.73M | $-2.68M |
| Debt Repayment | $- | $- | $- | $- | $-1.50M |
| Common Stock Issued | $271.00K | $252.00K | $- | $- | $- |
| Common Stock Repurchased | $-7.65M | $-822.00K | $-9.08M | $-13.35M | $-11.65M |
| Dividends Paid | $-6.94M | $-1.59M | $-378.00K | $- | $- |
| Other Financing Activities | $174.00K | $252.00K | $505.00K | $1.90M | $729.00K |
| Net Cash Used Provided by Financing Activities | $-14.42M | $-2.36M | $-8.95M | $-11.45M | $-12.42M |
| Effect of Forex Changes on Cash | $-254.00K | $3.00K | $-461.00K | $-50.00K | $91.00K |
| Net Change in Cash | $-4.72M | $1.42M | $-2.98M | $1.04M | $3.31M |
| Cash at End of Period | $16.89M | $21.61M | $20.19M | $23.17M | $22.14M |
| Cash at Beginning of Period | $21.61M | $20.19M | $23.17M | $22.14M | $18.82M |
| Operating Cash Flow | $12.20M | $6.83M | $7.96M | $16.27M | $18.33M |
| Capital Expenditure | $-2.25M | $-3.07M | $-1.53M | $-3.74M | $-2.68M |
| Free Cash Flow | $9.95M | $3.76M | $6.43M | $12.53M | $15.64M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $2.55M | $1.83M | $1.30M | $1.66M | $-656.00K | $629.00K | $1.97M | $1.02M | $-1.06M | $610.00K | $-1.42M | $1.14M | $79.00K | $3.32M | $4.91M | $1.72M | $3.81M | $2.45M | $3.82M | $1.66M |
| Depreciation and Amortization | $806.00K | $797.00K | $806.00K | $895.00K | $962.00K | $918.00K | $-356.00K | $1.36M | $1.59M | $984.00K | $1.38M | $987.00K | $1.33M | $1.35M | $966.00K | $1.40M | $1.21M | $2.25M | $1.42M | $1.29M |
| Deferred Income Tax | $-1.00M | $-515.00K | $659.00K | $-309.00K | $76.00K | $-1.70M | $-749.00K | $277.00K | $525.00K | $-1.75M | $-212.00K | $956.00K | $257.00K | $-1.08M | $614.00K | $43.00K | $552.00K | $-254.00K | $-1.22M | $2.07M |
| Stock Based Compensation | $1.72M | $917.00K | $756.00K | $796.00K | $750.00K | $978.00K | $946.00K | $817.00K | $823.00K | $602.00K | $406.00K | $-38.00K | $755.00K | $645.00K | $-79.00K | $668.00K | $983.00K | $464.00K | $838.00K | $1.16M |
| Change in Working Capital | $3.96M | $-3.96M | $-1.32M | $-293.00K | $266.00K | $3.73M | $199.00K | $-55.00K | $-916.00K | $-1.79M | $421.00K | $-2.38M | $1.62M | $-3.77M | $1.97M | $-777.00K | $-667.00K | $-5.96M | $4.49M | $-2.99M |
| Accounts Receivables | $1.36M | $-492.00K | $-872.00K | $26.00K | $219.00K | $-922.00K | $583.00K | $62.00K | $-413.00K | $1.33M | $-667.00K | $-395.00K | $814.00K | $-366.00K | $392.00K | $-104.00K | $-857.00K | $304.00K | $-1.43M | $612.00K |
| Inventory | $-970.00K | $-1.50M | $-63.00K | $-458.00K | $1.00M | $180.00K | $2.01M | $1.97M | $-1.35M | $-2.57M | $-745.00K | $-964.00K | $568.00K | $-45.00K | $-1.28M | $-349.00K | $330.00K | $-772.00K | $999.00K | $-699.00K |
| Accounts Payables | $526.00K | $-617.00K | $-1.08M | $744.00K | $-499.00K | $3.14M | $-2.34M | $-2.40M | $332.00K | $429.00K | $994.00K | $1.68M | $38.00K | $-1.89M | $1.58M | $1.40M | $-958.00K | $1.19M | $-494.00K | $114.00K |
| Other Working Capital | $3.04M | $-1.35M | $3.46M | $-605.00K | $-457.00K | $-2.40M | $-52.00K | $318.00K | $512.00K | $-973.00K | $1.41M | $-2.70M | $199.00K | $-1.46M | $1.28M | $-1.72M | $818.00K | $-6.68M | $5.42M | $-3.02M |
| Other Non Cash Items | $1.16M | $357.00K | $374.00K | $2.62M | $359.00K | $216.00K | $1.76M | $17.00K | $7.00K | $1.63M | $2.42M | $1.52M | $2.90M | $4.61M | $-7.00K | $890.00K | $-811.00K | $661.00K | $1.45M | $16.00K |
| Net Cash Provided by Operating Activities | $9.20M | $-583.00K | $2.58M | $3.09M | $1.76M | $4.76M | $3.76M | $3.44M | $967.00K | $-1.34M | $2.78M | $671.00K | $4.04M | $465.00K | $8.37M | $3.06M | $5.89M | $-1.05M | $9.35M | $3.21M |
| Investments in Property Plant and Equipment | $-492.00K | $-349.00K | $-278.00K | $-291.00K | $-543.00K | $-1.13M | $-513.00K | $-990.00K | $-837.00K | $-727.00K | $-266.00K | $-365.00K | $-521.00K | $-378.00K | $-480.00K | $-1.73M | $-572.00K | $-960.00K | $-574.00K | $-474.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $8.00K | $- | $- | $- | $- | $- | $- | $- | $7.00K | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $4.00K | $-2.25M | $- | $- | $- | $8.00K | $- | $- | $- | $-1.53M | $- | $- | $- | $7.00K | $- | $- | $-960.00K | $-2.68M | $- |
| Net Cash Used for Investing Activities | $-492.00K | $-345.00K | $-278.00K | $-291.00K | $-543.00K | $-1.13M | $-505.00K | $-990.00K | $-837.00K | $-727.00K | $-266.00K | $-365.00K | $-521.00K | $-378.00K | $-473.00K | $-1.73M | $-572.00K | $-960.00K | $-574.00K | $-474.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-500.00K |
| Common Stock Issued | $- | $- | $-644.00K | $145.00K | $- | $126.00K | $- | $- | $- | $- | $- | $- | $175.00K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-898.00K | $-1.46M | $-3.05M | $-1.25M | $-2.09M | $-1.26M | $-878.00K | $91.00K | $-19.00K | $-72.00K | $-504.00K | $-1.93M | $-3.02M | $-3.63M | $-4.05M | $-2.13M | $-4.67M | $-2.51M | $-150.00K | $-3.67M |
| Dividends Paid | $-502.00K | $-500.00K | $-503.00K | $-448.00K | $-455.00K | $-5.53M | $-445.00K | $-383.00K | $-381.00K | $-377.00K | $-378.00K | $- | $- | $- | $-5.24M | $- | $-5.24M | $- | $-72.00K | $- |
| Other Financing Activities | $-898.00K | $133.00K | $814.00K | $-766.00K | $- | $126.00K | $- | $-14.00K | $- | $121.00K | $- | $367.00K | $-170.00K | $308.00K | $375.00K | $273.00K | $991.00K | $257.00K | $74.00K | $323.00K |
| Net Cash Used Provided by Financing Activities | $-1.40M | $-1.83M | $-2.74M | $-2.46M | $-2.54M | $-6.67M | $-1.32M | $-306.00K | $-400.00K | $-328.00K | $-882.00K | $-1.56M | $-3.19M | $-3.32M | $-3.68M | $-1.85M | $-3.67M | $-2.25M | $-148.00K | $-3.85M |
| Effect of Forex Changes on Cash | $-308.00K | $466.00K | $-54.00K | $-292.00K | $256.00K | $-164.00K | $141.00K | $12.00K | $21.00K | $-171.00K | $762.00K | $-1.12M | $-92.00K | $-9.00K | $-6.00K | $-248.00K | $120.00K | $84.00K | $47.00K | $99.00K |
| Net Change in Cash | $7.00M | $-2.29M | $-491.00K | $46.00K | $-1.07M | $-3.20M | $2.08M | $2.16M | $-249.00K | $-2.57M | $2.39M | $-2.38M | $245.00K | $-3.25M | $4.22M | $-771.00K | $1.77M | $-4.18M | $8.67M | $-1.01M |
| Cash at End of Period | $21.59M | $14.60M | $16.89M | $17.38M | $17.33M | $18.41M | $21.61M | $19.53M | $17.37M | $17.62M | $20.19M | $17.80M | $20.17M | $19.93M | $23.17M | $18.95M | $19.73M | $17.96M | $22.14M | $13.46M |
| Cash at Beginning of Period | $14.60M | $16.89M | $17.38M | $17.33M | $18.41M | $21.61M | $19.53M | $17.37M | $17.62M | $20.19M | $17.80M | $20.17M | $19.93M | $23.17M | $18.95M | $19.73M | $17.96M | $22.14M | $13.46M | $14.48M |
| Operating Cash Flow | $9.20M | $-583.00K | $2.58M | $3.09M | $1.76M | $4.76M | $3.76M | $3.44M | $967.00K | $-1.34M | $2.78M | $671.00K | $4.04M | $465.00K | $8.37M | $3.06M | $5.89M | $-1.05M | $9.35M | $3.21M |
| Capital Expenditure | $-492.00K | $-349.00K | $-278.00K | $-291.00K | $-543.00K | $-1.13M | $-513.00K | $-990.00K | $-837.00K | $-727.00K | $-266.00K | $-365.00K | $-521.00K | $-378.00K | $-480.00K | $-1.73M | $-572.00K | $-960.00K | $-574.00K | $-474.00K |
| Free Cash Flow | $8.71M | $-932.00K | $2.30M | $2.80M | $1.21M | $3.63M | $3.25M | $2.45M | $130.00K | $-2.07M | $2.51M | $306.00K | $3.52M | $87.00K | $7.89M | $1.33M | $5.32M | $-2.01M | $8.78M | $2.74M |
LifeVantage Dividends
Explore LifeVantage's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
8.86%
Dividend Payout Ratio
236.30%
Dividend Paid & Capex Coverage Ratio
1.33x
LifeVantage Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.04 | $0.04 | March 03, 2025 | March 03, 2025 | March 17, 2025 | February 05, 2025 |
| $0.04 | $0.04 | December 02, 2024 | December 02, 2024 | December 16, 2024 | October 25, 2024 |
| $0.04 | $0.04 | September 09, 2024 | September 09, 2024 | September 17, 2024 | August 28, 2024 |
| $0.04 | $0.04 | May 31, 2024 | May 31, 2024 | June 14, 2024 | May 02, 2024 |
| $0.035 | $0.035 | February 29, 2024 | March 01, 2024 | March 15, 2024 | January 25, 2024 |
| $0.035 | $0.035 | November 30, 2023 | December 01, 2023 | December 15, 2023 | November 09, 2023 |
| $0.435 | $0.435 | September 07, 2023 | September 08, 2023 | September 22, 2023 | August 28, 2023 |
| $0.035 | $0.035 | May 31, 2023 | June 01, 2023 | June 15, 2023 | May 04, 2023 |
| $0.03 | $0.03 | February 28, 2023 | March 01, 2023 | March 15, 2023 | February 02, 2023 |
| $0.03 | $0.03 | November 30, 2022 | December 01, 2022 | December 15, 2022 | November 02, 2022 |
| $0.03 | $0.03 | September 01, 2022 | September 02, 2022 | September 15, 2022 | August 23, 2022 |
| $0.03 | $0.03 | May 16, 2022 | May 17, 2022 | May 31, 2022 | May 03, 2022 |
LifeVantage News
Read the latest news about LifeVantage, including recent articles, headlines, and updates.
LifeVantage Expands Global Reach with International Launch of the MB System™
SALT LAKE CITY, March 17, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation ® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, is extending its groundbreaking MindBody GLP-1 System™ to international markets. This expansion comes after a 49% year-over-year increase in fiscal Q2 revenue ending December 31, 2024, in the U.S., largely driven by the system's success, and clinical data on that formula reinforcing its effectiveness in supporting GLP-1 production.
LifeVantage Announces Launch of LV360 and Evolve Compensation Plan in Philippines, Taiwan, Hong Kong, and Singapore Markets
SALT LAKE CITY, March 03, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation ® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the successful launch of the Evolve Compensation Plan and other LV360 initiatives into the Philippines, Taiwan, Hong Kong, and Singapore. The transition went into effect in these markets on March 1, 2025, after the successful launch of LV360 into Canada, Mexico, and Europe last February, and the launch in the US, Australia, New Zealand and Japan in March 2023.
GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends
The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are permitted when drugs are listed on the FDA's list of drug shortages.
LifeVantage: Post-Earnings Selloff Provides Buying Opportunity
LifeVantage Corporation's Q2/FY2025 results were boosted by the successful launch of the MindBody GLP-1 system. LFVN revenues jumped by more than 40% on a sequential basis, while free cash flow of $8.7 million represented a new multi-year high. However, elevated commissions and incentive expenses impacted profitability, thus resulting in a rather mediocre Adjusted EBITDA margin of 9.6%.
LifeVantage Corporation (LFVN) Q2 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q2 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Reed Anderson – Managing Director-ICR Steve Fife – President and Chief Executive Officer Carl Aure – Chief Financial Officer Conference Call Participants Aaron Wukmir – Lake Street Capital Markets Alex Fuhrman – Craig-Hallum Capital Group Doug Lane – Water Tower Research Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's Second Quarter of Fiscal 2025 Results.
LifeVantage Declares Quarterly Dividend
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock, which will be paid March 17, 2025 to all stockholders of record at the close of business on March 3, 2025.
LifeVantage to Announce Second Quarter Fiscal Year 2025 Results on February 5, 2025
SALT LAKE CITY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its second quarter ended December 31, 2024, after the stock market closes on Wednesday, February 5, 2025. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
LifeVantage Welcomes Todd Thompson as Chief Information and Innovation Officer
Technology leader brings decades of expertise in innovation, scalability and customer-focused solutions to accelerate LifeVantage's growth and digital transformation Technology leader brings decades of expertise in innovation, scalability and customer-focused solutions to accelerate LifeVantage's growth and digital transformation
LifeVantage Launches 2025 Vision with “Drive ERA” Theme and International Expansion Plans for Evolve Compensation Plan and the MindBody GLP-1 System™
New Innovations and Incentives Empower Consultants to Accelerate Business Growth in 2025 New Innovations and Incentives Empower Consultants to Accelerate Business Growth in 2025
Undercovered Dozen: Fannie Mae, Civitas Resources, LifeVantage, ZenaTech +
The 'Undercovered' Dozen series highlights lesser-covered stocks, offering investment ideas and encouraging discussion among investors. Pacifica Yield highlights Brookfield Infrastructure's subordinated notes with a 32% discount opportunity and a 7.2% yield, backed by a strong balance sheet and diversified assets. Cerence Inc.'s partnership with Nvidia boosts its AI capabilities according to Uttam Dey, but caution is advised due to recent stock surge and potential volatility.
LifeVantage: Bold Move Into The GLP-1 Weight Loss Market Turns Out To Be A Major Winner - Buy
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs from the likes of Zepbound and Ozempic. The recent launch has exceeded expectations by a wide margin. On Wednesday, the company preannounced stellar Q2/FY2025 results. Preliminary Q2/FY2025 revenues of $67.5 million exceeded consensus expectations by more than 30% and active accounts of approximately 146,000 represented the highest level in almost two years.
LifeVantage to Participate in the 27th Annual ICR Conference
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the 27th Annual ICR Conference to be held January 13-15, 2025 in Orlando, FL.
LifeVantage Corporation (LFVN) Q1 2025 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q1 2025 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - President & Chief Executive Officer Carl Aure - Chief Financial Officer Conference Call Participants Douglas Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.
LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025
SALT LAKE CITY, Oct. 29, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024.
LifeVantage to Announce First Quarter Fiscal Year 2025 Results on October 29, 2024
SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2024, after the stock market closes on Tuesday, October 29, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
LifeVantage Introduces the MindBody GLP-1 System™ Transforming Weight Management into a Sustainable Lifestyle
Met With High Demand, the Dual-Product System is Clinically Shown to Increase GLP-1 by 140% on average to Balance Hunger Hormones and Reduce Cravings, Supporting Sustainable Weight and Visceral Fat Loss While Maintaining Muscle ‡Ω
LifeVantage to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
SALT LAKE CITY, Sept. 04, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer and Carl Aure, Chief Financial Officer will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9-11, 2024 in New York, NY.
LifeVantage Corporation (LFVN) Q4 2024 Earnings Call Transcript
LifeVantage Corporation (NASDAQ:LFVN ) Q4 2024 Earnings Conference Call August 28, 2024 4:30 PM ET Company Participants Reed Anderson - ICR Steve Fife - President & CEO Carl Aure - CFO Conference Call Participants Douglas Lane - Water Tower Research Operator Good day, ladies and gentlemen. Thank you for standing by.
LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2024
SALT LAKE CITY, Aug. 28, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2024.
LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service
SALT LAKE CITY, Aug. 26, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company's Board of Directors effective today. The appointment comes after the Board conducted a comprehensive search to identify a candidate with transformational digital skills and identified Mr. Anbalagan as an exceptional choice.
LifeVantage Concludes Rise Retreat in Park City with Exclusive Preview of New Innovative Weight Management Solution
Event highlighted new weight management products while fostering strategic collaboration and recognition among Consultants Event highlighted new weight management products while fostering strategic collaboration and recognition among Consultants
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2024 Results on August 28, 2024
SALT LAKE CITY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its fourth quarter and full fiscal year ended June 30, 2024, after the stock market closes on Wednesday, August 28, 2024. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.
LifeVantage To Host “LifeVantage Open House” Virtual Calls on July 23 and 24
Calls will highlight how company is ahead of industry with recent transformation initiatives, innovative compensation plan, award-winning, activating products, and vibrant entrepreneurial community Calls will highlight how company is ahead of industry with recent transformation initiatives, innovative compensation plan, award-winning, activating products, and vibrant entrepreneurial community
LifeVantage To Participate in Upcoming Investor Conferences
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will be participating in the following investor conferences during the month of June:
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LFVN.